Business Context and Reporting Period
This Form 8-K Current Report was filed by Syndax Pharmaceuticals, Inc. on December 7, 2020. The filing addresses the termination of a material definitive agreement and the submission of updated corporate disclosures.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. It is a current report focused on corporate events rather than periodic financial performance.
Material Changes
- Termination of Sales Agreement: The Company terminated its "at the market" equity offering program (Sales Agreement) with Cowen and Company, LLC, effective December 7, 2020.
- No Shares Sold: Prior to termination, the Company had not sold any shares of Common Stock under this agreement, and no further sales will occur under this specific agreement.
- Updated Disclosures: The Company filed a preliminary prospectus supplement containing updated descriptions of its business to supplement prior filings, including the 2019 Annual Report on Form 10-K.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, outlook, or management commentary on future performance. The primary risk or contingency noted is the cessation of the specific equity offering program with Cowen, though the Company has filed updated disclosures regarding its business operations.
Investor Verification Checklist
- Verify the status of the Company's current capital raising activities following the termination of the Cowen Sales Agreement.
- Review the "Updated Corporate Disclosure" (Exhibit 99.1) for material changes to the business description compared to the 2019 Form 10-K.
- Confirm that no shares were issued under the terminated agreement, as stated in the filing.